Summary of Study ST003575
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002205. The data can be accessed directly via it's Project DOI: 10.21228/M8M52Z This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Download mwTab file (text) | Download mwTab file(JSON) | Download data files (Contains raw data)
| Study ID | ST003575 |
| Study Title | Lipidomic Profiling of a Preclinical Model of Streptozotocin induced Diabetic Cardiomyopathy |
| Study Summary | Lipidomic profiling was conducted on plasma from ~22 week old, male FVB/NJ mice that were subjected to five consecutive daily intraperitoneal (i.p.) injections of citrate buffer vehicle (non-diabetic) or STZ (55 mg/kg in 0.02 mol/L citrate buffer, pH 4.5) to induce diabetes at 6 weeks of age. Mice were monitored for 16 weeks of untreated diabetes. |
| Institute | Baker Heart and Diabetes Institute |
| Laboratory | Metabolomics |
| Last Name | Tham |
| First Name | Yow |
| Address | 75 Commercial Rd |
| yowkeat.tham@baker.edu.au | |
| Phone | 0430502623 |
| Submit Date | 2024-11-13 |
| Num Groups | 2 |
| Total Subjects | 17 |
| Num Males | 17 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2025-02-13 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002205 |
| Project DOI: | doi: 10.21228/M8M52Z |
| Project Title: | Lipidomic Profiling of a Preclinical Model of Streptozotocin induced Diabetic Cardiomyopathy |
| Project Summary: | Despite advances in diabetes care, people with type 1 diabetes (T1D) continue to have a shorter life expectancy than the general population due to a higher risk of cardiovascular disease. These heart complications are the leading cause of death in people with diabetes. People with diabetes develop heart failure without other common risk factors like high blood pressure or coronary heart disease. This condition is known as ‘diabetic cardiomyopathy’. Unfortunately, the exact causes of diabetes-induced heart failure in people with T1D are not fully understood. Given the lack of effective treatment for diabetic cardiomyopathy, the discovery of clear diagnostic lipid biomarkers from preclinical models of T1D could be key to managing disease progression. |
| Institute: | Baker Heart and Diabetes Institute |
| Laboratory: | Metabolomics |
| Last Name: | Tham |
| First Name: | Yow |
| Address: | 75 Commercial Rd |
| Email: | yowkeat.tham@baker.edu.au |
| Phone: | 0430502623 |
Subject:
| Subject ID: | SU003704 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Genotype Strain: | FVB/NJ |
| Age Or Age Range: | approx 22 weeks old |
| Gender: | Male |
| Animal Housing: | 2-3 mice per cage |
| Animal Light Cycle: | 12:12-h light–dark cycle |
| Animal Feed: | Specialty Feeds Irradiated Rat and Mouse Standard Chow Diet |
| Animal Water: | ad libitum |
| Species Group: | Mammals |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Sample source | Treatment |
|---|---|---|---|
| SA389853 | 37155 | Plasma | Citrate buffer vehicle |
| SA389854 | 37257 | Plasma | Citrate buffer vehicle |
| SA389855 | 37159 | Plasma | Citrate buffer vehicle |
| SA389856 | 37244 | Plasma | Citrate buffer vehicle |
| SA389857 | 37241 | Plasma | Citrate buffer vehicle |
| SA389858 | 37158 | Plasma | Citrate buffer vehicle |
| SA389859 | 37253 | Plasma | STZ |
| SA389860 | 37148 | Plasma | STZ |
| SA389861 | 37245 | Plasma | STZ |
| SA389862 | 37142 | Plasma | STZ |
| SA389863 | 37152 | Plasma | STZ |
| SA389864 | 37237 | Plasma | STZ |
| SA389865 | 37154 | Plasma | STZ |
| SA389866 | 37239 | Plasma | STZ |
| SA389867 | 37247 | Plasma | STZ |
| SA389868 | 37248 | Plasma | STZ |
| SA389869 | 37144 | Plasma | STZ |
| Showing results 1 to 17 of 17 |
Collection:
| Collection ID: | CO003697 |
| Collection Summary: | Blood was collected in EDTA tubes (Becton Dickinson #365975) from mice via cardiac puncture after mice were injected with KXA: 100:10:1.2 mg/kg (i.p.). Tubes were centrifuged at 4000g for 15 minutes, plasma was collected and stored in -80℃ freezer until processed for lipid extractions. |
| Sample Type: | Blood (plasma) |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR003713 |
| Treatment Summary: | At 6 weeks of age, aged-matched male mice were randomly allocated into non-diabetic and diabetic groups. Each day prior to administration of streptozotocin (STZ) (AdipoGen Life Sciences, San Diego, CA, USA, batch number LOTA00514) or citrate buffer vehicle, mice were fasted for 4–6 h. Following fasting, mice received five consecutive daily intraperitoneal (i.p.) injections of citrate buffer vehicle (non-diabetic) or STZ (55 mg/kg in 0.02 mol/L citrate buffer, pH 4.5) to induce diabetes and were monitored for 16 weeks. Mice were culled by exsanguination under anesthesia (KXA: 100:10:1.2 mg/kg, i.p.). |
| Treatment: | Induction of Type 1 Diabetes |
| Treatment Compound: | streptozotocin |
| Treatment Route: | intraperitoneal injection |
| Treatment Dosevolume: | 55 mg/kg STZ |
| Treatment Doseduration: | 5 consecutive daily injections |
| Treatment Vehicle: | Citrate buffer |
| Animal Endp Euthanasia: | KXA: 100:10:1.2 mg/kg |
Sample Preparation:
| Sampleprep ID: | SP003711 |
| Sampleprep Summary: | Lipid extraction was conducted using 10ul of sample using the single phase chloroform methanol method. 10ul of internal standards and 100 μL of buthanol:methanol (1:1) were added to samples before the mixture was vortexed. Samples were then transferred to a bath sonicator, and sonicated for 1 hour at water temperature below 25°C. Samples were then centrifuged at 13000 rpm for 10 minutes. The supernatant was then transferred to corresponding glass vials and stored at -80°C until analysis. |
| Processing Storage Conditions: | On ice |
| Extract Storage: | -80℃ |
Combined analysis:
| Analysis ID | AN005870 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Agilent 1290 Infinity II |
| Column | Agilent ZORBAX Eclipse Plus C18 (100 x 2.1 mm, 1.8μm) |
| MS Type | ESI |
| MS instrument type | Triple quadrupole |
| MS instrument name | Agilent 6495 QQQ |
| Ion Mode | POSITIVE |
| Units | pmol/mL |
Chromatography:
| Chromatography ID: | CH004459 |
| Chromatography Summary: | The running solvent consisted of solvent A: 50% H2O / 30% acetonitrile / 20% isopropanol (v/v/v) containing 10mM ammonium formate and 5uM medronic acid, and solvent B: 1% H2O / 9% acetonitrile / 90% isopropanol (v/v/v) containing 10mM ammonium formate. We utilized a stepped linear gradient with a 16-minute cycle time per sample and a 1 µL sample injection. To increase throughput, we used a dual column set up to equilibrate the second column while the first is running a sample. The sample analytical gradient was as follows: starting with a flow rate of 0.4 mL/minute at 15% B and increasing to 50% B over 2.5 minutes, then to 57% over 0.1 minutes, to 70% over 6.4 minutes, to 93% over 0.1 minute, to 96% over 1.9 minutes and finally to 100% over 0.1 minute. The solvent was then held at 100% B for 0.9 minutes (total 12.0 minutes). Equilibration was started as follows: solvent was decreased from 100% B to 15% B over 0.2 minutes and held until a total of 16 minutes. The next sample is injected and the columns are switched. |
| Instrument Name: | Agilent 1290 Infinity II |
| Column Name: | Agilent ZORBAX Eclipse Plus C18 (100 x 2.1 mm, 1.8μm) |
| Column Temperature: | 45°C |
| Flow Gradient: | Starting with a flow rate of 0.4 mL/minute at 15% B and increasing to 50% B over 2.5 minutes, then to 57% over 0.1 minutes, to 70% over 6.4 minutes, to 93% over 0.1 minute, to 96% over 1.9 minutes and finally to 100% over 0.1 minute. The solvent was then held at 100% B for 0.9 minutes (total 12.0 minutes). Equilibration was started as follows: solvent was decreased from 100% B to 15% B over 0.2 minutes and held until a total of 16 minutes. |
| Flow Rate: | 0.4 mL/min |
| Solvent A: | 50% water/30% acetonitrile/20% isopropanol; 10 mM ammonium formate; 5 μM medronic acid |
| Solvent B: | 1% water/9% acetonitrile/90% isopropanol; 10 mM ammonium formate |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS005590 |
| Analysis ID: | AN005870 |
| Instrument Name: | Agilent 6495 QQQ |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| MS Comments: | Details previously published in https://doi.org/10.1016/j.chembiol.2018.10.008 Analysis of plasma extracts was performed on an Agilent 6495 QQQ mass spectrometer with an Agilent 1290 series HPLC system and a ZORBAX eclipse plus C18 column (2.1 x 100 mm 1.8 μm, Agilent) with the thermostat set at 60°C. Mass spectrometry analysis was performed in positive ion mode with dynamic scheduled multiple reaction monitoring (MRM). Mass spectrometry settings and MRM transitions for each lipid class, subclass and individual species are shown in Tables 1 and S1. The solvent system consisted of solvent A) 50% H2O / 30% acetonitrile / 20% isopropanol (v/v/v) containing 10mM ammonium formate and solvent B) 1% H2O / 9% acetonitrile / 90% isopropanol (v/v/v) containing 10mM ammonium formate. We utilized a stepped linear gradient with a 15-minute cycle time per sample and a 1μL sample injection. The gradient was as follows; starting with a flow rate of 0.4 mL/minute at 10% B and increasing to 45% B over 2.7 minutes, then to 53% over 0.1 minutes, to 65% over 6.2 minutes, to 89% over 0.1 minute, to 92% over 1.9 minutes and finally to 100% over 0.1 minute. The solvent was then held at 100% B for 0.8 minutes (total 11.9 minutes). Equilibration was as follows, solvent was decreased from 100% B to 10% B over 0.1 minute and held for an additional 0.9 minutes. Flow rate was then switched to 0.6 mL/minute for 1 minute before returning to 0.4 mL/minute over 0.1 minutes. Solvent B was held at 10% B for a further 0.9 minutes at 0.4 mL/minutes for a total cycle time of 15 minutes. The following mass spectrometer conditions were used; gas temperature, 150°C, gas flow rate 17L/min, nebulizer 20psi, Sheath gas temperature 200°C, capillary voltage 3500V and sheath gas flow 10L/min. Isolation widths for Q1 and Q3 were set to “unit” resolution (0.7 amu). PQC samples consisting of a pooled set of 6 healthy individuals were incorporated into the analysis at 1 PQC per 18 plasma samples. TQC consisted of PQC extracts which were pooled and split into individual vials to provide a measure of technical variation from the mass spectrometer only. These were included at a ratio of 1 TQC per 18 plasma samples. TQCs were monitored for changes in peak area, width and retention time to determine the performance of the LC-MS/MS analysis and were subsequently used to align for differential responses across the analytical batches. |
| Ion Mode: | POSITIVE |
